173
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
COMPARATIVE ANALYSIS OF THE IMPACT OF TRADITIONAL AND MODERN
MEDICINES IN GASTRITIS
Ibragimova G.B.
Suyunov N.D.
Tashkent Pharmaceutical Institute, Tashkent city, Republic of Uzbekistan
e-mail: gulmiraibragimova1911@gmail.com
https://doi.org/10.5281/zenodo.17332472
Relevance:
gastritis is an inflammation of the gastric mucosa, which can occur in acute or
chronic forms. Its causes include Helicobacter pylori infection, acid hyper secretion, and other
contributing factors. Since the 1990s, traditional proton pump inhibitors, e.g., omeprazole have been
the standard therapy for gastritis and Helicobacter pylori eradication. However, in recent years, the
global rate of antibiotic resistance has reached 20–30%, and long-term use of proton pump inhibitors
has been associated with certain risks, such as gastric atrophy and vitamin deficiencies. As an
alternative, modern potassium-competitive acid blockers, e.g., vonoprazan have been introduced.
These agents inhibit gastric acid secretion more rapidly and for longer durations, potentially
improving Helicobacter pylori eradication efficacy by 10–20%. According to the findings of studies
conducted between 2023 and 2025, the role of potassium-competitive acid blockers in the treatment
of gastritis is becoming increasingly significant. In particular, their advantages in improving the
efficacy of Helicobacter pylori eradication and reducing the progression of gastric mucosal injury
have been scientifically demonstrated. Therefore, potassium-competitive acid blockers are
recommended in clinical practice as an optimal therapeutic option for patients and are expected to
become a main therapeutic approach in the coming years for the treatment of gastritis and
Helicobacter pylori-related diseases.
Purpose of the study:
gastritis (acute and chronic forms) in treatment traditional proton pump
inhibitors proton pump inhibitors and between modern potassium-competitive acid blockers
potassium-competitive acid blockers efficiency and Systematic safety monitoring comparison.
Materials and methods:
this study was based on a systematic literature review and meta-
analysis, including randomized clinical trials and meta-analyses retrieved from PubMed and Google
Scholar databases from 2020–2025.
Results:
the results of the meta-analysis showed the superiority of potassium-competitive acid
blockers over proton pump inhibitors. The pooled Risk Ratio for Helicobacter pylori eradication
efficacy was 1.17, (95% Confidence interval: 1.11–1.22, I² = 28%), indicating that potassium-
competitive acid blockers were 17% more effective. The Odds Ratio for the rate of peptic ulcers and
gastritis was 1.25 (95% Confidence interval: 1.08–1.45, I² = 40%), and accelerated mucosal
regeneration in atrophic changes. There was no difference in side effects (diarrhea, headache) (Risk
Ratio = 1.01, 95% Confidence interval: 0.88–1.16). Potassium-competitive acid blockers were more
effective in the acute and chronic subgroups of gastritis resistant more effective in forms Risk Ratio
= 1.18.
Table
Proton pump inhibitors and potassium-competitive acid blockers drugs gastritis results
of a meta-analysis of effectiveness
174
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
Meson
Proton pump
inhibitors
Potassium-
competitive acid
blockers
Risk Ratio/
Odds
Ratio, 95%
Confidence
interval
I² (%)
Helicobacter pylori
eradication
78.0%
92.0%
1.17 (1.11–1.22)
28
Injury how much
76.0%
89.0%
1.25 (1.08–1.45)
40
Side effects
13.0%
13.2%
1.01 (0.88–1.16)
15
Conclusions:
in gastritis, potassium-competitive acid blockers show statistical and clinical
superiority over proton pump inhibitors in acid suppression and Helicobacter pylori eradication,
which serves to stop inflammation and reduce the risk of complications. Recommendation: in first-
line therapy, a potassium-competitive acid blockers-based triple regimen «Vonoprazan 20 mg +
amoxicillin + clarithromycin, 14 days» is preferred; in Uzbekistan, taking into account resistance, it
should be combined with a bismuth-based regimen.
